PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
51 hedge funds and large institutions have $73.4M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
50% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 20
Holders
51
Holding in Top 10
–
Calls
$275K
Puts
$138K
Top Buyers
| 1 | +$1.92M | |
| 2 | +$1.03M | |
| 3 | +$814K | |
| 4 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
+$662K |
| 5 |
BlackRock
New York
|
+$433K |
Top Sellers
| 1 | -$3.36M | |
| 2 | -$3.01M | |
| 3 | -$2.41M | |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$2.02M |
| 5 |
EP
Eversept Partners
New York
|
-$933K |